Arvaya Healthcare Ltd (524723)
சுருக்கம்
The board meets on 13 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 13 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 13 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 4 நவ. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 13 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Arvaya Healthcare Ltd-இன் இயக்குநர் குழுக் கூட்டம் 13 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, Arvaya Healthcare's revenue was ₹0.1 Cr, and net profit ₹-0.9 Cr (a bigger loss than a year earlier); the operating margin was -803.5%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.1 | — | — |
| செயல்பாட்டு லாபம் | ₹-0.8 | நஷ்டம் அதிகரித்தது | நஷ்டம் அதிகரித்தது |
| நிகர லாபம் | ₹-0.9 | நஷ்டம் அதிகரித்தது | நஷ்டம் அதிகரித்தது |
| EPS (₹) | -0.18 | நஷ்டம் குறைந்தது | நஷ்டம் அதிகரித்தது |
| செயல்பாட்டு லாப வரம்பு | -803.5% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Arvaya Healthcare Limited has scheduled an earnings conference call for Monday, November 16, 2026, at 3:00 PM IST. The management will discuss the financial and operational performance for Q2 and H1 ended September 30, 2026. Key participants will include CMD Kaushal Uttam Shah, CEO Salil Sriram Shetty, and CFO Ranganath Abhiram. The company currently holds a market cap of Rs 248 Cr despite having near-zero operational revenue and TTM net losses of Rs 2 Cr.
- Earnings conference call scheduled for November 16, 2026, at 3:00 PM IST
- Focus of call is operational and financial performance for Q2 and H1 ended September 30, 2026
- Senior management including Chairman & MD, CEO, and CFO will attend
- Universal dial-in numbers provided: +91 22 6280 1102 and +91 22 7115 8003
Arvaya Healthcare Limited's Rights Issue Committee has approved and adopted the Draft Letter of Offer (DLOF) for a proposed rights issue of partly paid-up equity shares aggregating up to ₹205.80 crore. The face value of the shares will be ₹10 each. This planned fundraise is massive relative to the company's size, representing approximately 83% of its current market capitalization of ₹248 crore and over 3.5x its net worth of ₹58 crore. The company is filing the DLOF with BSE and SEBI to seek in-principle listing approval.
- Approved Draft Letter of Offer for a Rights Issue aggregating up to ₹20,580.00 lakhs (₹205.80 crore)
- Proposed issue comprises partly paid-up equity shares with a face value of ₹10 each
- Fundraise represents ~83% of current market capitalization (₹248 crore)
- Filing DLOF with BSE Limited to obtain in-principle listing approval under Regulation 28(1)
Arvaya Healthcare Limited issued a revised board meeting outcome authorising its Rights Issue Committee to finalise the Draft Letter of Offer (DLOF) for a proposed rights issue of up to ₹210 crore (₹21,000.00 lakhs) in partly paid-up equity shares. This follows earlier board approval granted on July 11, 2026. The proposed fundraise of ₹210 crore represents roughly 85% of the company's current market capitalisation of ₹248 crore and over 3.6x its net worth of ₹58 crore. Final terms including issue price, rights entitlement ratio, and record date are yet to be determined.
- Board authorised Rights Issue Committee to finalise and file DLOF for up to ₹21,000.00 lakhs (₹210 crore)
- Proposed issue involves partly paid-up equity shares under Section 62(1)(a) of the Companies Act, 2013
- DLOF to be filed with BSE Limited for in-principle approval
- Final terms such as issue price, entitlement ratio, and record date remain to be decided
Arvaya Healthcare Limited's Board has approved the Draft Letter of Offer (DLOF) for a proposed Rights Issue of partly paid-up equity shares aggregating up to ₹210.00 crore. This fundraise is massive relative to the company's current scale, representing approximately 84.7% of its current market capitalization of ₹248 crore and nearly 3.6x its net worth of ₹58 crore. The terms including the issue price, rights entitlement ratio, and record date will be determined by the Rights Issue Committee later. The Board also approved conducting a postal ballot with NSDL for shareholder approval.
- Board approved Draft Letter of Offer for Rights Issue up to ₹21,000.00 lakhs (₹210.00 crore)
- Proposed issuance comprises partly paid-up equity shares to eligible shareholders
- Fundraise represents ~84.7% of current market capitalization of ₹248 crore
- Approval granted for postal ballot via e-voting through NSDL to obtain shareholder consent
Arvaya Healthcare has completed the acquisition of a 100% equity stake in Sushodha Institute of Gastroenterology Private Limited (SIGPL), acquiring 1,84,374 equity shares effective November 1, 2026. Following the transaction, SIGPL has become a wholly-owned subsidiary of Arvaya Healthcare. For a company that generated Rs 0 Cr in TTM revenue and reported a TTM net loss of Rs 2 Cr, this acquisition represents a major strategic addition to its healthcare operations. Deal value and acquisition cost details were not disclosed in the filing.
- Acquired 1,84,374 equity shares, representing 100% of the equity share capital of SIGPL
- SIGPL became a wholly-owned subsidiary of the company effective November 1, 2026
- Follows earlier intimation regarding the proposed acquisition dated October 24, 2026
- Acquisition value and financial details of the target were not disclosed in the document
Arvaya Healthcare Ltd has scheduled a Board of Directors meeting on November 4, 2026. The board will consider approving the Draft Letter of Offer (DLOF), objects, and fund deployment for a proposed Rights Issue. Additionally, directors will review proposed material related-party transactions subject to shareholder approval. The company currently holds a market cap of ₹248 Cr with negligible operational revenue and negative TTM earnings.
- Board meeting scheduled for November 4, 2026
- Agenda includes approval of Draft Letter of Offer (DLOF) for a proposed Rights Issue
- Will decide on utilisation of proceeds and deployment of funds for the Rights Issue
- Board to consider material related-party transactions requiring audit committee and shareholder approvals
Arvaya Healthcare Limited disclosed an acquisition of 5,91,129 equity shares by Executive Director Bidari Kotresh Anilkumar on a preferential basis via a share swap on October 24, 2026. Following this allotment, his personal stake increased from 17,20,873 shares (3.58%) to 23,12,002 shares (4.45%). The transaction expands the equity base of the micro-cap distributor, which reported virtually zero TTM revenue and TTM losses of Rs -2 Cr.
- 5,91,129 equity shares allotted to Executive Director Bidari Kotresh Anilkumar via preferential share swap
- Post-acquisition holding rises from 17,20,873 shares (3.58%) to 23,12,002 shares (4.45%)
- Transaction and intimation date recorded as October 24, 2026
- Company market cap stands at Rs 248 Cr despite negligible operations (TTM revenue of Rs 0 Cr)
Arvaya Healthcare has approved the allotment of 38,71,854 equity shares at ₹40 per share (aggregating to ₹15.49 crore) on a preferential basis to 47 shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL). The transaction is structured as a share swap for consideration other than cash. This expands the company's paid-up equity base from ₹48.02 crore to ₹51.89 crore. The value of this swap corresponds to roughly 6.2% of the company's current market cap of ₹248 crore.
- Allotment of 38,71,854 equity shares of face value ₹10 at an issue price of ₹40 (including premium of ₹30)
- Total transaction size of ₹15,48,74,160 executed via share swap for consideration other than cash
- Paid-up share capital increases from ₹48,02,18,570 to ₹51,89,37,110
- Allotment distributed across 47 non-promoter shareholders of SIGPL
Arvaya Healthcare Ltd has scheduled a Board meeting on October 24, 2026, to consider and approve the allotment of 38,71,854 equity shares on a preferential basis for consideration other than cash. The shares will be issued to the shareholders of Sushodha Institute of Gastroenterology Private Limited ('SIGPL'). At the current market price of Rs 116.0, this allotment translates to an implied transaction value of approximately Rs 44.9 crore, representing ~18% of the company's Rs 248 crore market cap. This signals an inorganic business addition for Arvaya Healthcare, which currently reports negligible TTM revenue.
- Board meeting scheduled on October 24, 2026, to approve preferential share allotment
- Allotment of 38,71,854 equity shares to shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL)
- Issue is on a preferential basis for consideration other than cash
- Implied value of shares stands at ~Rs 44.9 crore based on the current market price of Rs 116.0
Arvaya Healthcare has received in-principle approval from BSE dated October 12, 2026, for a preferential allotment of 38,71,854 equity shares. The shares carry a face value of Rs 10 each and are priced at an issue price of Rs 40 per share, implying a total fundraise of approximately Rs 15.49 crore. This proposed capital infusion equals about 6.2% of the company's current market capitalization of Rs 248 crore and represents about 26.7% of its existing net worth of Rs 58 crore. For a company with negligible TTM revenues (Rs 0 crore) and a TTM net loss of Rs -2 crore, the fresh capital provides liquidity but comes at a steep discount to the current market price of Rs 116.
- Received BSE in-principle approval on October 12, 2026
- Approval granted for preferential issue of 38,71,854 equity shares
- Face value fixed at Rs 10 per equity share
- Issue price set at Rs 40 per share, totaling Rs 15.49 crore
Arvaya Healthcare has incorporated a wholly owned subsidiary, Arvaya Insurance Broking Private Limited, on September 17, 2026. The parent is investing Rs 80,00,000 in cash to subscribe to 8,00,000 equity shares of Rs 10 each (100% initial capital). The new entity has received an NOC from the Insurance Regulatory and Development Authority of India (IRDAI) to act as a Direct Insurance Broker in General and Life Insurance. This marks a diversification into financial services for the company, which reported near-zero revenue in FY26.
- Incorporated wholly owned subsidiary 'Arvaya Insurance Broking Private Limited' on September 17, 2026
- Cash subscription cost of Rs 80,00,000 for 8,00,000 equity shares of Rs 10 each
- Received NOC from IRDAI to pursue Direct Insurance Broking in General and Life Insurance
- Listed parent holds 100% initial paid-up share capital and control
Arvaya Healthcare Limited has announced that its 41st Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 3:00 PM IST through video conferencing. The company has dispatched letters containing the web link to the Annual Report and AGM notice to 3,092 shareholders who do not have registered email addresses. The cut-off date to determine e-voting eligibility is September 14, 2026, with the e-voting window active between September 18 and September 20, 2026.
- 41st Annual General Meeting scheduled for September 21, 2026, at 3:00 PM IST via VC/OAVM
- Physical notice weblinks dispatched to 3,092 shareholders on August 28, 2026
- Cut-off date for AGM e-voting eligibility set as September 14, 2026
- E-voting period scheduled from September 18, 2026, to September 20, 2026
Arvaya Healthcare has issued notice for its 41st Annual General Meeting to be held on September 21, 2026. Key special business includes approval of material related party transactions (RPTs) aggregating up to Rs 370 Crore across 9 promoter, subsidiary, and group entities for FY27. Additionally, the company seeks shareholder approval to acquire intellectual property and copyright assets from DEFIB Institute of Health Solutions LLP (an entity connected to Executive Director Bidari Kotresh Anilkumar) funded through Rights Issue proceeds.
- 41st AGM scheduled for Monday, September 21, 2026 at 3:00 PM via Video Conferencing.
- Shareholder approval sought for FY27 RPT limits totaling Rs 370 Crore across 9 entities, including promoter entities (Rs 40-50 Cr each).
- Proposed acquisition of IP and copyright portfolio from DEFIB Institute of Health Solutions LLP funded out of Rights Issue proceeds.
- Executive Director Bidari Kotresh Anilkumar holds 3.58% in Arvaya and is a Designated Partner in DEFIB.
Arvaya Healthcare's Board has approved the acquisition of the copyright and intellectual property portfolio of DEFIB INSTITUTE OF HEALTH SOLUTIONS LLP for a consideration not exceeding ₹10 crore. The transaction is structured strictly as an IP assignment and will be funded out of the proceeds of the company's Rights Issue. As a Material Related Party Transaction, it is subject to statutory compliance and shareholder approval under SEBI LODR regulations. The board revised the scope during the meeting from a previously planned slump-sale acquisition.
- Acquisition consideration capped at not exceeding ₹10 Crores based on independent valuation
- Funded out of proceeds from the company's Rights Issue
- Structured strictly as an assignment of Copyright and IP portfolio, not a slump sale
- Requires shareholder approval under SEBI LODR Regulation 23 for material related-party transactions
Arvaya Healthcare Ltd has scheduled a Board of Directors meeting on August 26, 2026, to consider and approve a related party transaction. The proposal involves acquiring the business undertaking of Navahmedi Solution Private Limited via a slump sale, encompassing intellectual property, assets, and liabilities. The acquisition is intended to be funded out of rights issue proceeds. Key financial details, including acquisition valuation and transaction consideration, will depend on the outcome of the board meeting.
- Board meeting scheduled for August 26, 2026 to evaluate the transaction.
- Proposed acquisition of business undertaking from Navahmedi Solution Private Limited via slump sale.
- Scope includes transfer of intellectual property, assets, and liabilities.
- Acquisition to be funded utilizing proceeds from the company's rights issue.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
